Screener
ArriVent BioPharma, Inc. AVBP Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(43,320) | $(64,387) |
| Adjustment to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 5,485 | 2,271 |
| Amortization/Accretion of bond discounts/premiums | (559) | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (2,561) | (1,591) |
| Other assets | 37 | — |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s stock-based comp?
- ArriVent BioPharma, Inc. (AVBP) reported stock-based comp of $5.49M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s stock-based comp changed year-over-year?
- ArriVent BioPharma, Inc.'s stock-based comp increased by 141.5% year-over-year, from $2.27M to $5.49M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s stock-based comp?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s stock-based comp has grown at a 274.0% compound annual growth rate (CAGR), from $895K to $12.52M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about ArriVent BioPharma, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude